Challenges in tuberculosis drug research and development, Nat Med, vol.13, p.17342142, 2007. ,
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future, J Infect Dis, vol.205, issue.2, pp.241-250, 2012. ,
Bacteriologic basis of short-course chemotherapy for tuberculosis, Clin Chest Med, vol.1, issue.2, p.6794976, 1980. ,
, World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017.
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications, Int J Tuberc Lung Dis, vol.3, pp.231-279, 1999. ,
1931-1971: a critical review, with particular reference to the medical profession, pp.1-11, 1979. ,
Treatment of multidrug-resistant tuberculosis: evidence and controversies, Int J Tuberc Lung Dis, vol.10, p.16898365, 2006. ,
, Abstract to the 38th World Conference on Lung Health, pp.8-12, 2000.
Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative, Int J Tuberc Lung Dis, vol.8, p.15581210, 2004. ,
Randomized trials to optimize treatment of multi-drug resistant tuberculosis, PLoS Med, vol.4, issue.11, p.292, 2007. ,
The diarylquinoline TMC207 for multidrug-resistant tuberculosis, N Engl J Med, vol.360, p.19494215, 2009. ,
Delamanid for multidrug-resistant pulmonary tuberculosis, N Engl J Med, vol.366, issue.23, p.22670901, 2012. ,
Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation, Eur Respir J, vol.44, issue.6, p.25435528, 2014. ,
, , 2019.
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial, Trials, vol.15, p.25199531, 2009. ,
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries, Int J Tuberc Lung Dis, vol.22, issue.1, p.29149917, 2018. ,
, Geneva: World Health Organisation, WHO treatment guidelines for drug-resistant tuberculosis: 2016 update (WHO/HTM/TB/2016.04), 2016.
, WHO handbook for guideline development. Geneva: World Health Organisation, 2014.
Guidance for Industry Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications, pp.800-835, 2003. ,
, World Health Organization, World Health Organisation: Target Regimen Profiles for TB Treatment (WHO/HTM/TB/2016.16). (Available at, 2016.
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model, PLoS Med, vol.14, issue.1, p.28045934, 2017. ,
Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials, Clin Infect Dis, vol.65, issue.1, p.28402396, 2017. ,
Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities, Int J Tuberc Lung Dis, vol.14, p.20392344, 2010. ,
Adaptive clinical trials in tuberculosis: applications, challenges and solutions, Int J Tuberc Lung Dis, vol.19, issue.6, p.25946350, 2015. ,
OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis, N Engl J Med, vol.371, issue.17, p.25337748, 2014. ,
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis, N Engl J Med, vol.371, issue.17, p.25196020, 2014. ,
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N Engl J Med, vol.371, issue.17, p.25337749, 2014. ,
A Patient-Level Pooled Analysis of Treatment Shortening Regimens for Drug-Susceptible Pulmonary Tuberculosis, Nature Med, vol.24, issue.11, p.30397355, 2018. ,
, Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, Geneva: World Health Organization, vol.17, pp.14-16, 2018.
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape, PLoS Med, vol.16, issue.3, 2019. ,